FNCH — Finch Therapeutics Income Statement
0.000.00%
- $2.49m
- -$18.27m
- $0.11m
- 26
- 56
- 20
- 26
Annual income statement for Finch Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 10.2 | 7.72 | 18.5 | 0.861 | 0.107 |
Cost of Revenue | |||||
Gross Profit | 9.84 | 7.72 | — | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 31.3 | 47.2 | 76.7 | 116 | 84.6 |
Operating Profit | -21.1 | -39.4 | -58.2 | -116 | -84.5 |
Total Net Non Operating Interest Income / Expense | |||||
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -20.8 | -39.3 | -58.2 | -115 | -78.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -20.8 | -39.3 | -58.2 | -115 | -74.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -20.8 | -39.3 | -58.2 | -115 | -74.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -20.8 | -39.3 | -58.2 | -115 | -74.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -13.1 | -25 | -45.9 | -54.9 | -26.4 |
Dividends per Share |